Multiple myeloma (MM) with high-risk (HR) genetic abnormalities has poor prognosis, despite the use of novel therapeutic agents. However, the individual contribution of specific HR genetic abnormalities or their co-occurrence to poor outcomes, especially in the era of novel agents, remains unclear. This study evaluated the impact of multi-hit TP53 (del(17p) and TP53 mutation or ≥ 2 TP53 mutations) compared with other HR abnormalities on progression-free survival (PFS), overall survival (OS) and blood signature in a real-world cohort of 204 patients with MM treated with novel agents (median follow-up 28 months). Patients with multi-hit TP53 (10.4%) had the shortest PFS and OS compared with those with single HR abnormalities (p ≤ 0.011) or with co-occurrence of ≥ 2 other HR abnormalities (p ≤ 0.002), regardless of therapy line. The relative risk of early progression in patients with multi-hit TP53 was almost three times higher than that of patients with other HR abnormalities. The prevalence of TP53 alterations increased in later disease stages: multi-hit TP53 was detected in 7.6% of patients with ≤ 1 prior therapy line and in 36.4% of patients with ≥ 2 prior lines. Patients with multi-hit TP53 also differed in blood signature, particularly in counts of white blood cells, lymphocytes, serum creatinine and β2-microglobulin levels compared with those with other HR abnormalities. In conclusion, multi-hit TP53 is associated with the poorest survival among all HR subgroups in MM. Considering that TP53 alterations accumulate during MM progression and are associated with drug resistance even in the context of novel therapies, our study further emphasizes the need for routine evaluation of both del(17p) and TP53 mutations. Patients with multi-hit TP53 should be prioritized for inclusion in trials of novel therapeutic strategies.

Department of Hemato Oncology Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc Olomouc Czech Republic

Department of Immunology Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc Olomouc Czech Republic

Zobrazit více v PubMed

Abu Za’nouneh FJ, Ababneh O, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, et al. Variability of definition of high-risk multiple myeloma across phase III clinical trials. EJHaem. 2023;4(2):454–8. 10.1002/jha2.675 PubMed PMC

Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone. Leukemia. 2010;24(3):623–8. 10.1038/leu.2009.273. PubMed DOI

Avet-Loiseau H, Davies FE, Samur MK, Corre J, D’Agostino M, Kaiser MF, et al. International myeloma society/international myeloma working group consensus recommendations on the definition of high-risk multiple myeloma. J Clin Oncol. 2025;20(24):2739–51. 10.1200/JCO-24-01893. PubMed DOI

Baysal M, Demirci U, Umit E, Kirkizlar HO, Atli EI, Gurkan H, et al. Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance. Sci Rep. 2020;10(1):5991. 10.1038/s41598-020-62885-0. PubMed DOI PMC

Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–24. 10.1016/S0140-6736(21)00933-8. PubMed DOI

Chin M, Sive JI, Allen C, Roddie C, Chavda SJ, Smith D, et al. Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival. Blood Cancer J. 2017;7(9):e610. 10.1038/bcj.2017.76. PubMed DOI PMC

Corre J, Perrot A, Hulin C, Caillot D, Stoppa AM, Facon T, et al. Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods. Leukemia. 2021;35(12):3600–3. 10.1038/s41375-021-01250-0. PubMed DOI

De Ramón C, Rojas EA, Cardona-Benavides IJ, Mateos MV, Corchete LA, Gutiérrez NC. Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome. Br J Haematol. 2022;199(3):344–54. 10.1111/bjh.18410. PubMed DOI PMC

Durand R, Descamps G, Bellanger C, Dousset C, Maïga S, Alberge JB, et al. A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics. Blood. 2024;143(13):1242–58. 10.1182/blood.2023021581. PubMed DOI

Ferri GM, Yildirim C, Do NV, Brophy M, Park JS, Munshi NC, et al. Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma. Blood Adv. 2025;9(1):78–88. 10.1182/bloodadvances.2024014125. PubMed DOI PMC

Joerger AC, Stiewe T, Soussi T. TP53: the unluckiest of genes? Cell Death Differ. 2025;32(2):219–24. 10.1038/s41418-024-01391-6. PubMed DOI PMC

Jovanović KK, Escure G, Demonchy J, Willaume A, Van de Wyngaert Z, Farhat M, et al. Deregulation and targeting of TP53 pathway in multiple myeloma. Front Oncol. 2019;8:665. 10.3389/fonc.2018.00665. PubMed DOI PMC

Kaiser MF, Sonneveld P, Cairns DA, Raab MS, San-Miguel Izquierdo J, Zhang R, et al. Co-occurrence of cytogenetic abnormalities and high-risk disease in newly diagnosed and relapsed/refractory multiple myeloma. J Clin Oncol. 2025. 10.1200/JCO-24-01253. PubMed DOI PMC

Kortüm KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016;128(9):1226–33. 10.1182/blood-2016-02-698092. PubMed DOI PMC

Kriegova E, Fillerova R, Minarik J, Savara J, Manakova J, Petrackova A, et al. Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities. Sci Rep. 2021;11(1):14671. 10.1038/s41598-021-93835-z. PubMed DOI PMC

Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G, Soussi T. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res. 2013; 41(Database issue):D962–9. 10.1093/nar/gks1033 PubMed PMC

Li Y, Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene. 2007;26(15):2220–5. 10.1038/sj.onc.1210311. PubMed DOI

Martello M, Poletti A, Borsi E, Solli V, Dozza L, Barbato S, et al. Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma. Blood Cancer J. 2022;12(1):15. 10.1038/s41408-022-00610-y. PubMed DOI PMC

Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495–505. 10.1056/NEJMoa2203478. PubMed DOI PMC

Munawar U, Roth M, Barrio S, Wajant H, Siegmund D, Bargou RC, et al. Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model. Sci Rep. 2019;9(1):18062. 10.1038/s41598-019-54407-4. PubMed DOI PMC

Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16. 10.1056/NEJMoa2024850. PubMed DOI

Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, et al. Outcomes of autologous stem cell transplantation in patients with ultra-high-risk multiple myeloma. Transplant Cell Ther. 2023;29(12):757–62. 10.1016/j.jtct.2023.08.031. PubMed DOI PMC

Petrackova A, Minarik J, Sedlarikova L, Libigerova T, Hamplova A, Krhovska P, et al. Diagnostic deep-targeted next-generation sequencing assessment of TP53 gene mutations in multiple myeloma from the whole bone marrow. Br J Haematol. 2020;189(4):e122-5. 10.1111/bjh.16547. PubMed DOI

Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548–67. 10.1002/ajh.25791. PubMed DOI

Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802–24. 10.1002/ajh.27422. PubMed DOI PMC

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48. 10.1016/S1470-2045(14)70442-5. PubMed DOI

Rees MJ, D’Agostino M, Leypoldt LB, Kumar S, Weisel KC, Gay F. Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies. Am Soc Clin Oncol Educ Book. 2024;44(3):e433520. 10.1200/EDBK_433520. PubMed DOI

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24. 10.1038/gim.2015.30. PubMed DOI PMC

Shen M, Yang G, Li X, Geng C, Huang Z, Chen W. At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China. Leuk Lymphoma. 2021;62(12):2992–3001. 10.1080/10428194.2021.1948032. PubMed DOI

Sreedharanunni S, Singla S, Balakrishnan A, Singh A, Jamwal M, Singh N, et al. The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma. Pathology. 2024;56(4):556–64. 10.1016/j.pathol.2023.12.415. PubMed DOI

Tsallos D, Ikonen N, Miettinen JJ, Majumder MM, Eldfors S, Västrik I, et al. Multi-omic and functional screening reveal targetable vulnerabilities in TP53 mutated multiple myeloma. medRxiv. 2024.08.23.24312359. 10.1101/2024.08.23.24312359

van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410–27. 10.1016/S0140-6736(21)00135-5. PubMed DOI

Visram A, Dasari S, Anderson E, Kumar S, Kourelis TV. Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. Blood Cancer J. 2021;11(3):45. 10.1038/s41408-021-00440-4. PubMed DOI PMC

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33(1):159–70. 10.1038/s41375-018-0196-8. PubMed DOI PMC

Wang PF, Yee CW, Gorsh B, Zichlin ML, Paka P, Bhak RH, et al. Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study. Leuk Lymphoma. 2023;64(2):398–406. 10.1080/10428194.2022.2140284. PubMed DOI

Wang Z, Burigotto M, Ghetti S, Vaillant F, Tan T, Capaldo BD, et al. Loss-of-function but not gain-of-function properties of mutant TP53 are critical for the proliferation, survival, and metastasis of a broad range of cancer cells. Cancer Discov. 2024;14(2):362–79. 10.1158/2159-8290.CD-23-0402. PubMed DOI PMC